Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TherapeuticsMD Inc TXMD

Healthcare
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD... see more

Recent & Breaking News (NDAQ:TXMD)

Five Star Equities Issues New Research Reports on BSFT, CIDM, POL and TXMD

Accesswire February 3, 2014

TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap(TM) (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy (VVA)

Business Wire January 28, 2014

TherapeuticsMD Initiates Phase 3 Clinical Trial of Its Progesterone Candidate (TX 12-002-HR) for Treatment of Secondary Amenorrhea

Business Wire January 24, 2014

TherapeuticsMD Announces Issuance of U.S. Patent Covering Natural Combination Hormone Replacement Formulations and Therapies, Including TX 12-001-HR

Business Wire January 22, 2014

TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection

Business Wire January 6, 2014

TherapeuticsMD Names Randall S. Stanicky to Board of Directors

Business Wire December 18, 2013

TherapeuticsMD Receives Notice of Allowance for Patent Covering Platform Technology of Oral Combination Bioidentical 17?-Estradiol and Progesterone

Business Wire December 9, 2013

TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer

Business Wire December 4, 2013

TherapeuticsMD To Present At 25th Annual Piper Jaffray Healthcare Conference

Business Wire November 22, 2013

TherapeuticsMD Applauds Congressional Leadership on Passage of Drug Quality and Security Act

Business Wire November 19, 2013

TherapeuticsMD Reports Third Quarter 2013 Financial Results

Business Wire November 4, 2013

TherapeuticsMD Appoints Sebastian Mirkin, M.D. as Chief Medical Officer

Business Wire October 23, 2013

TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy (VVA)

Business Wire October 22, 2013

TherapeuticsMD to Host Third Quarter 2013 Earnings Call

Business Wire October 21, 2013

TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting

Business Wire October 18, 2013

Phase 1 Data Presented on First Oral Combination 17?-Estradiol and Progesterone Capsule to Treat Menopausal Symptoms Being Developed for FDA Review

Business Wire October 9, 2013

TherapeuticsMD Announces Pricing of Offering of Common Stock

Business Wire September 25, 2013

TherapeuticsMD Begins Patient Enrollment in Pivotal Phase 3 Clinical Trial of TX 12-001-HR to Treat Symptoms of Menopause and Provide Endometrial Protection

Business Wire September 5, 2013

TherapeuticsMD to Present at Stifel Nicolaus 2013 Healthcare Conference

Business Wire August 29, 2013

TherapeuticsMD Initiates Phase I Study of Estradiol VagiCap(TM) for VVA

Business Wire August 12, 2013